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Infantile hemangioma (IH), the most common tumor of infancy, is characterized by an initial
proliferation during infancy followed by spontaneous involution over the next 5–10 years,
often leaving a fibro-fatty residuum. IH is traditionally considered a tumor of the microvas-
culature. However, recent data show the critical role of stem cells in the biology of IH with
emerging evidence suggesting an embryonic developmental anomaly due to aberrant pro-
liferation and differentiation of a hemogenic endothelium with a neural crest phenotype
that possesses the capacity for endothelial, hematopoietic, mesenchymal, and neuronal
differentiation. Current evidence suggests a putative placental chorionic mesenchymal core
cell embolic origin of IH during the first trimester. This review outlines the emerging role
of stem cells and their interplay with the cytokine niche that promotes a post-natal envi-
ronment conducive for vasculogenesis involving VEGFR-2 and its ligand VEGF-A and the
IGF-2 ligand in promoting cellular proliferation, and the TRAIL-OPG anti-apoptotic pathway
in preventing cellular apoptosis in IH. The discovery of the role of the renin–angiotensin
system in the biology of IH provides a plausible explanation for the programed biologic
behavior and the β-blocker-induced accelerated involution of this enigmatic condition. This
crucially involves the vasoactive peptide, angiotensin II, that promotes cellular proliferation
in IH predominantly via its action on the ATIIR2 isoform. The role of the RAS in the biology
of IH is further supported by the effect of captopril, an ACE inhibitor, in inducing accel-
erated involution of IH. The discovery of the critical role of RAS in IH represents a novel
and fascinating paradigm shift in the understanding of human development, IH, and other
tumors in general.
Keywords: infantile hemangioma, renin–angiotensin system, beta-blocker, angiotensin-converting enzyme
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INTRODUCTION
Infantile hemangioma (IH) affects 4–10% of infants with a
predilection for female, Caucasian, low birth weight, and prema-
ture infants (1–3). A higher incidence of IH has also been observed
following amniocentesis (4), chorionic villous sampling (CVS) (5),
and pre-eclampsia (6). IH has traditionally been regarded as a
tumor of the microvasculature characterized by the proliferation
of immature endothelial cells (ECs) (7) (Figure 1A). The expres-
sion of stem cell markers in IH has led to the notion that stem cells
are recruited into the lesion (8, 9). However, recent data demon-
strating a primitive signature on the endothelium of proliferating
IH has shed new light on the biology of this tumor. This, along with
the appreciation of the role of various cytokine signaling pathways
in IH, has resulted in a paradigm shift in the understanding of this
enigmatic condition.
This review outlines recent data pointing to a placental embolic
origin of IH during early fetal life (10) and a post-natal conducive
environment that supports proliferation and differentiation of the
embolized primitive cells. The co-expression of multiple primi-
tive markers in IH suggests an aberrant embryonic developmen-
tal anomalous nature of this condition (11) with evidence of a
hemogenic endothelium (12) that possesses the capability for neu-
ronal (13), mesenchymal (9, 14), endothelial (13), and hematopoi-
etic (15) differentiation. Insights into the niche-environment
within IH that regulates this primitive endothelium including the
vascular endothelial growth factor (VEGF) system, the insulin-like
growth factor (IGF) system, the TRAIL-osteoprotegerin (OPG)
anti-apoptotic pathway, and the renin–angiotensin system (RAS),
provide clues into the post-natal environment that modulates the
programed biologic behavior of IH and underscores current and
future novel therapies.
PLACENTA AND INFANTILE HEMANGIOMA
PLACENTAL ANTIGENS
The expression of glucose transporter-1 (GLUT-1) protein on the
endothelium of IH (Figure 1B) was first reported in 2000 (16).
The demonstration of GLUT-1 in IH and the placental syncy-
tiotrophoblast microvilli and basement membranes (17), and the
unique co-expression of the placental antigens, merosin, Lewis Y
antigen, FCγRIII, and type 3-iodothyronine deiodinase (18–20),
has led to the speculation of a placental embolic origin of IH.
PLACENTAL CELLS
Earlier work by Bree et al. (21) investigating the expression of the
markers of placental trophoblasts, alkaline phosphatase, human
placental lactogen (hPL), and cytokeratins 7 and 8, shows that
none of these markers are expressed in IH. We have subsequently
demonstrated the unique co-expression of human chorionic
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gonadotropin (hCG) and hPL, but not cytokeratin 7 and human
leukocyte antigen-G (HLA-G), on the endothelium of proliferat-
ing IH (10) – a phenotypic signature of placental chorionic villous
mesenchymal core cells (PCVMCCs). This led us to hypothesize a
PCVMCC origin of IH and propose that these cells are embolized
to the developing fetus proper in which they become embedded
and integrated (10). We further hypothesized that embolization
of PCVMCCs within the first trimester coinciding with the first
migration of neural crest cells along their somitic routes (10) that
occurs within the first month of gestation (22), leads to integration
of these cells along the neural crest migratory routes manifesting as
segmental lesions (Figure 2), while embolization later in gestation
results in discrete lesion(s) (Figure 3) (10).
This hypothesis, if proven, would account for the increased
incidence of IH in infants born following amniocentesis and CVS,
with a higher incidence in CVS (4, 5). Amniocentesis and CVS are
typically performed at 15 and 11 weeks of gestation, respectively
(4), suggesting that earlier placental intervention is more likely
to result in embolization of the PCVMCCs. A Cochrane review
shows increased incidence of discrete IH lesions following amnio-
centesis and CVS (23), which are performed after the wave of
neural crest migration that typically occurs within the first month
of gestation (22).
FIGURE 1 | DAB staining of proliferating infantile hemangioma
showing the abundance of microvessels with an inner endothelium
expressing the endothelial marker, CD34 [(A) brown], and an outer
pericyte layer expressing smooth muscle actin [(A,B) red]. The inner
endothelial layer also expresses GLUT-1 [(B) brown], the
immunohistochemical marker for infantile hemangioma. Cell nuclei are
counterstained with hematoxylin [(A,B) blue]. Original magnification 400×.
STEM CELLS IN INFANTILE HEMANGIOMA
EMBRYONIC-LIKE STEM CELLS
The presence of embryonic stem cell (ESC) markers during the
proliferative phase of IH with reduced expression as the lesion
involutes, has been observed by several research groups (24, 25).
The expression of ESC markers, such as Oct-4,SSEA-4,and STATS-
3, has been demonstrated on the endothelium of proliferating IH
(25). Interestingly, another population of cells expressing the ESC
markers, Nanog (25, 26), SALL4 (24), and CD133 (24), has been
localized in the interstitium of IH. More recent work has con-
firmed the presence of these markers within proliferating IH at
the transcriptional level (27). It remains to be determined whether
one set of cells gives rise to the other, or whether there are two
distinct populations of embryonic-like stem cells within prolifer-
ating IH. However, the observation of co-expression of tryptase
and Nanog in an interstitial cell population in proliferating IH,
suggests that these interstitial cells represent a primitive myeloid
phenotype, which we propose to have arisen from the putative
hemogenic endothelium of IH (28). The exact role for these prim-
itive myeloid cells with a mast cell phenotype is the focus of our
ongoing research.
NEURAL CREST CELLS
Infantile hemangioma commonly presents as a discrete lesion(s)
(Figure 3). A sub-group of IHs present as plaque-like lesions,
distributed in a segmental manner (29) (Figure 2), forming a
pattern similar to the meso-ectodermal fusion lines, along the
neural crest somite migratory routes (30). The observation that
some segmental IHs are associated with midline structural anom-
alies, constituting PHACES syndrome (31) (Figure 4), has led us
to investigate the involvement of neural crest cells (32). We have
shown the expression of the neural crest markers, p75, SOX-9, and
SOX-10, on the endothelium of proliferating IH, thus displaying
a neural crest phenotype (32). Interestingly, neural crest cells are
the only cells that are developmentally capable of forming both
mesenchymal as well as ectodermal lineage tissues (33). The co-
expression of neural crest and ESC markers in the endothelium
of proliferating IH, however, suggests that cells with neural crest
phenotype are downstream to cells expressing ESC markers (34).
Khan et al. (13) have demonstrated the ability of IH-derived cells
to undergo neuronal differentiation, a downstream ectodermal
FIGURE 2 | Segmental infantile hemangioma in the “fronto-nasal” (A), “maxillary” (B), and “mandibular” (C) distribution.
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lineage. Similarly, these IH-derived cells possess the potential for
mesenchymal differentiation (9, 14).
PRIMITIVE ENDOTHELIAL PHENOTYPE
Our investigations show that the endothelium of proliferating
IH expresses a number of primitive lineage markers including
the primitive mesoderm marker (brachyury) (12), mesenchymal
markers (vimentin, CD29 and Pref-1) (14), and hematopoietic
markers [ACE, GATA-2, Tal-1, and hemoglobin ζ (HBZ)] (12,
15, 35, 36). This unique co-expression pattern suggests that the
endothelium of proliferating IH possesses a primitive phenotype
with a hemogenic endothelium signature (37, 38), and also the
ability for cells derived from proliferating IH to form mature
ECs (13). The presence of an endothelial progenitor cell (EPC)
population within proliferating IH lesions (8) and the circulation
of affected patients (39), led to the earlier hypothesis that these
FIGURE 3 | A discrete proliferating infantile hemangioma on the forehead (A), scalp (B), cheek (C), and upper lip (D) of affected infants.
FIGURE 4 | A girl with segmental cervico-facial infantile hemangioma associated with a sternal cleft constituting PHACES syndrome. Reproduced with
permission from the Journal of Clinical Pathology (32).
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cells are the origin of IH. However, the demonstration of a more
primitive phenotype of the endothelium of proliferating IH, sug-
gests that the circulating EPCs represent a more downstream
population, rather than being the origin of IH (12).
HEMATOPOIETIC DIFFERENTIATION
The demonstration of a hemogenic endothelium phenotype
within proliferating IH has led us to investigate the functional
capability of IH to undergo hematopoietic differentiation. We have
shown that proliferating IH explant-derived cells possess the capa-
bility to undergo spontaneous erythropoiesis in vitro (15), with
evidence of the presence of intermediate blast colonies charac-
terized by the expression of VEGFR-2, CD34, CD133, and ACE
(15, 25). We have further demonstrated the expression of the
fetal hemoglobin, HBZ chain, and erythropoietin receptor, on the
endothelium of proliferating IH (15). This, along with the func-
tional ability of proliferating IH-derived cells to form erythrocytes
expressing HBZ, suggests the capability of the endothelium of
proliferating IH to undergo primitive erythropoiesis (15, 40). A
recent report by Doege et al. (41) shows exogenous erythropoietin
administration as an independent risk factor for developing IH,
in pre-term infants. This observation implies the existence of the
putative stem cell origin for IH, and the administration of erythro-
poietin creates an environment conducive for the development
of IH.
MESENCHYMAL DIFFERENTIATION
A mesenchymal progenitor cell (MPC) population within IH
has been proposed to give rise to the fibro-fatty deposition that
occurs during spontaneous involution of IH (9). These MPCs
have been assumed to be recruited into the IH lesion, from
either local niches or the bone marrow (9). However, the expres-
sion of the pre-adipocyte marker, Pref-1, on the endothelium of
proliferating IH points to the phenotypic hemogenic endothe-
lium being the origin of these MPCs (14, 42). The notion of
an endothelial phenotype giving rise to mesenchymal progeni-
tors has been previously reported for a CD34+ population (43),
although the authors highlighted that the CD34+ cells were also
CD31−, which taken in context, highlights CD34 as a primi-
tive marker for both hematopoietic and endothelial (44) prog-
enitors, as well as MPCs. The ability for IH-derived cells to
undergo terminal mesenchymal differentiation (9, 14) confirms
the existence of an MPC population within proliferating IH,
potentially giving rise to the fibro-fatty residuum of involuted
lesions.
CYTOKINE NICHE
THE VASCULAR ENDOTHELIAL GROWTH FACTOR SYSTEM
Vascular endothelial growth factor has been implicated in the pro-
liferation of IH (45) with the demonstration of the local produc-
tion of VEGF by the endothelium of IH (46). The VEGF-A isoform
has been suggested to play a key role in the biology of IH, along
with other hypoxia-induced factors that are up-regulated during
proliferation of IH, by promoting an environment conducive for
post-natal vasculogenesis (47).
Despite the inferred role of VEGF-A in IH, it was not until
work by Jinnin et al. (48) that the demonstration of the VEGFR-
2 isoform, coupled with the reduced decoy receptor VEGFR-1,
led to the proposed predominant action of the VEGF-A ligand in
promoting enhanced signaling via VEGFR-2 phosphorylation (48,
49) possibly with the aid of the molecular chaperone, COSMC
(50). The expression of VEGF-A during proliferation of IH has
more recently been localized to cells away from the endothelium
(51), with corticosteroids inhibiting the effect on the vasculo-
genic potential of IH-derived stem cells, via reduction in VEGF-A
expression (51).
THE INSULIN-LIKE GROWTH FACTOR SYSTEM
The insulin-like growth factors, IGF-1 and IGF-2, share a 60%
homology in their amino acid sequences (52). The receptors for
these cytokines are predominantly IGF receptors 1 and 2, dif-
fering by either the presence or absence of the β or α subunits,
respectively (53, 54). Interestingly IGF-2 has been reported to
be predominantly produced by proliferating IH, decreasing as
the lesion involutes (42). Furthermore, the expression of IGF-2
has been localized to the endothelium of IH (42, 55). Further
evidence using our in vitro explant model of IH (56) shows
the effect of exogenous IGF-2 on stimulating outgrowths of
cells from IH (42). Despite the increased knowledge about the
role of IGF-2 in the biology of IH, there is currently no data
on the expression of either of the two IGF receptors within
IH. This is potentially an important pathway to investigate as
IGF-2 is also known to bind to both insulin receptor (IR) iso-
forms A and B (53), with the IR-A isoform being predomi-
nantly expressed during human fetal development. It may be
possible that IGF-2 is the ligand for the IGF receptors and the
IRs in IH, with IH being an embryonic developmental anomaly
(15, 57).
THE TRAIL-OSTEOPROTEGERIN ANTI-APOPTOTIC PATHWAY
Osteoprotegerin, a soluble decoy death receptor for tumor necro-
sis factor-related apoptosis-inducing ligand (TRAIL), has recently
been localized to the endothelium of IH and is up-regulated in
proliferating lesions (58). Furthermore, the expression of TRAIL
and its receptors, death receptors 4 and 5 and decoy death recep-
tors 1 and 2, has been demonstrated at steady levels throughout
the three phases of IH development (58). OPG is a pro-tumor
survival factor (59) and its reduced levels during involution of
IH (58) may account for the reduction in cellular density typically
seen in involuted lesions (60), through TRAIL-mediated apoptosis.
This is intriguing as clusterin/ApoJ, a glycoprotein that has been
shown to be up-regulated during involution of IH (60), stimu-
lates tumor necrosis factor-α (TNF-α) (61), a ligand for TRAIL, in
association with cellular apoptosis (62). Therefore, OPG is impli-
cated in anti-apoptosis during the proliferative phase of IH with
the development of a putative environment conducive for cellu-
lar senescence through the indirect up-regulation of TNF-α, by
clusterin/ApoJ (61), coupled with the decreased production of
OPG (58).
THE RENIN–ANGIOTENSIN SYSTEM
The role of the RAS in the biology of IH has been recently
demonstrated by the expression of angiotensin-converting enzyme
(ACE) (Figure 5A) and the angiotensin II receptor 2 (ATIIR2)
(Figure 5B) isoform; the effect of angiotensin II (ATII) in inducing
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FIGURE 5 | Immunofluorescent staining of proliferating infantile
hemangioma demonstrating the endothelium, with CD34 (green, A &
B), also expressing ACE (A, red) and ATIIR2 isoform (B, red). Original
magnification: 400x.
IH-derived blast cell proliferation (25); and the promotion of
cellular proliferation in IH by ATII via the activation of ATIIR2,
in vitro (63).
Serum levels of renin are approximately five folds that of adults
within the first 3 months of life, tapering to three times that of the
adult levels at 3–12 months of age, twice that of the adult levels
at 1–4 years of age, with gradual reduction to normal adult levels
from 8 years of age (64). The tapering levels of renin from birth
through infancy and childhood (64) mirror the programed growth
pattern for IH (65).
Renin levels have also been shown to be physiologically
higher in female (compared with male), Caucasian (compared
with black), and premature (compared with full-term) infants
(66). This may account for the higher incidence of IH in these
demographic groups (6).
High levels of renin, which convert the precursor angiotensino-
gen into angiotensin I, indirectly lead to high levels of ATII within
IH that promotes a niche conducive for cellular proliferation
(67). We have proposed the role of RAS in spontaneous and RAS
modulator-induced accelerated involution of IH via its influence
on the levels of both VEGF and OPG (67), although these remain
the topic of our ongoing research. Based on previous reports, we
have hypothesized that ATII promotes both VEGF and OPG secre-
tion and maintain an environment favorable for vasculogenesis
and anti-apoptosis (66) (Figure 6). However, these remain to be
conclusively determined.
THE RENIN–ANGIOTENSIN SYSTEM AND NOVEL THERAPIES
β-BLOCKERS
The β-blockers, propranolol (68) and acetabutolol (69) were
serendipitously discovered in 2008, by two independent French
groups to cause accelerated involution of IH. Propranolol is now
the preferred treatment for problematic proliferating IH (70, 71).
Subsequently other β-blockers including timolol (72), nadolol
(73), and atenolol (74) have also been described in the treatment
of IH.
Various hypotheses have been advanced to account for the
observed β-blocker-induced accelerated involution of IH (75)
including vasoconstriction (71), decreased levels of VEGF, and
fibroblast growth factor-2, leading to inhibition of angiogenesis
(76) and the induction of apoptosis in proliferating ECs (77).
β-adrenergic receptors are expressed throughout the body
with β1-receptors predominantly located in the heart and kid-
ney, and β2-receptors predominantly located in peripheral blood
vessels, skeletal muscle, and the lungs (78). In the kidney, β-
adrenoreceptor blockade leads to inhibition of renin release and
consequently results in modulation of the RAS (79).
The capability of β1 and non-selective β-blockers to induce
accelerated involution of IH implies the common action of this
class of drugs, via their modulation of RAS, rather than their
inhibitory effects on the sympathetic nervous system or circulating
catecholamines via β-adrenoreceptors blockade.
β-BLOCKERS CURRENTLY IN USE FOR THE TREATMENT OF INFANTILE
HEMANGIOMA
Propranolol, a non-selective β-blocker, is now the preferred
treatment for problematic proliferating IH at a dosage of 2–
3 mg/kg/day (80). However, the optimal escalation regimen,
dosage, and treatment duration remain unknown. We have
demonstrated that low-dose propranolol at 1.5–2.0 mg/kg/day is
efficacious and has minimal complications (80) (Figure 7).
Acebutolol, a selective β1-blocker, is administered at a dosage
of 8–10 mg/kg/day, with a clinical response generally observed
1 month after initiation of the treatment (81). Comparison of the
efficacy of propanolol and acebutolol is currently the subject of a
trial at the University Hospital at Montpellier, registered with the
Clinical Trials US National Institute of Health.
Atenolol shows promise as an alternative to propranolol
for IH. It is administered as a once daily dosing regimen of
1 mg/kg/day (82). As atenolol is a cardio-selective β-blocker,
there is theoretically a reduced risk of adverse respiratory effects,
which is beneficial in patients prone to bronchospasm whilst on
propranolol (83).
Nadolol, a synthetic non-specific β-receptor antagonist, has
been advocated for the treatment of IH as it is thought to have
a better safety profile and greater compliance (its longer half-life
allows for less frequent dosing) compared to propranolol (73).
Nadolol is commenced at 0.5 mg/kg/day in two divided doses. The
dosage is increased according to response on a weekly basis by
0.5 mg/kg up to a maximum of 4 mg/kg/day. As nadalol does not
cross the blood brain barrier, there is a potentially reduced risk of
nightmares and long-term memory loss (73).
Timolol, a topical non-selective β-blocker, administered as
0.5% timolol maleate ophthalmic solution (two drops per dose)
(72) or as a gel preparation applied twice daily directly onto the
IH (84), has been described with promising results in superficial
lesions.
SIDE EFFECTS OF β-BLOCKERS IN THE TREATMENT OF INFANTILE
HEMANGIOMA
The side effects of β-blockers in the treatment of IH include
hypotension, bradycardia, hypoglycemia, bronchospasm, hyper-
kalemia, nightmares, and gastrointestinal upsets (70). Propra-
nolol, at 2–3 mg/kg/day for the treatment for proliferating IH,
is associated with variable complication rates up to 61.2% (85). A
meta-analysis of 41 reports with a mean dosage of 2.12 mg/kg/day
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FIGURE 6 | Our proposed model of infantile hemangioma (IH) accounting
for the observed programed biologic behavior and accelerated
involution induced by modulators of the RAS, β-blockers, or ACE
inhibitors. IH is caused by aberrantly displaced/embolized placental chorionic
villous mensenchymal core cells into the fetus proper, which gives rise to a
primitive mesoderm-derived hemogenic endothelium with a neural crest
phenotype regulated by the RAS. This hemogenic endothelium differentiates
into stem cells of neuro-glial, mesenchymal, endothelial, and hematopoietic
lineages with downstream mesenchymal and erythropoetic and potentially
myeloid differentiation capabilities. During the proliferative phase of IH, high
levels of renin indirectly lead to high levels of ATII resulting in aberrant
proliferation of the hemogenic endothelium and secretion of vascular
endothelial growth factor (VEGF) from the accumulating mesenchymal stem
cells (MSCs), both leading to proliferation of the endothelial progenitor cells
(EPCs) and downstream endothelial cells (ECs). High levels of ATII also lead to
over-expression of the TRAIL decoy receptor, osteoprotogerin (OPG)
preventing apoptosis of the hemogenic endothelium, MSCs, and EPCs, with
further proliferation and accumulation of these cellular elements and ECs.
High levels of ATII also prevent terminal differentiation of MSCs to
downstream adipocytes, further increasing the accumulation of MSCs.
During the involuting phase of IH, reduced levels of ATII indirectly caused by
decreasing levels of renin, ease accumulation of EPCs and ECs. Reduced
levels of ATII also allow termination differentiation of MSCs into adipocytes
resulting in a fibro-fatty residuum. Inhibition of renin by β-blockers or ACEi
leads to reduced levels of ATII resulting in accelerated involution of IH.
Reproduced with permission from Plastic and Reconstructive Surgery (67).
shows complications occurring in 31% of patients (86). We (80)
have previously shown that accelerated involution of IH occurs
at a lower dosage of propranolol than that currently used. An
individual patient’s minimal therapeutic dosage to treatment
response can be determined by using a stepwise escalation reg-
imen, thereby reducing side effects and treatment costs while
improving outcomes. We have confirmed that propranolol, at
1.5–2 mg/kg/day, administered in divided doses is effective for
treating proliferating IH with minor complications of 6.8% (87).
We have also shown that treatment needs to continue to an
average age of 14.2 months to avoid rebound growth (80, 87),
reflecting the rapid tapering of circulating renin levels at that
age (64).
ACE INHIBITORS
Confirmation of the role of the RAS in the biology of IH and the
observed effect of β-blockade has been supported by a prospec-
tive observational clinical study using captopril, an ACE inhibitor
(66) (Figure 8). Treatment of IH with low-dose captopril at
1.5 mg/kg/day (compared to the cardiovascular dosage of up to
4 mg/kg/day) resulted in accelerated involution of IH in seven
out of the eight subjects, with a more gradual response in the
remaining patient (66). However, a retrospective review of IH
patients treated with captopril for steroid-induced cardiomyopa-
thy by Christou et al. (88) did not show any favorable results,
although the dosage and duration of captopril administration was
not reported.
CONCLUSION
Infantile hemangioma is traditionally considered a tumor of the
microvasculature (2, 7). However, recent data shows the critical
role of stem cells in the biology of IH (11, 27, 89, 90) with emerging
evidence suggesting an embryonic developmental anomaly due to
aberrant proliferation and differentiation of a hemogenic endothe-
lium (12) with a neural crest phenotype (32), that possesses the
capacity for endothelial (13), hematopoietic (15), mesenchymal
(14), and neuronal (9) differentiation (Figure 6). Current evidence
suggests a putative PCVMCCs embolic origin of IH during the
first trimester (10) (Figure 6), although this remains to be conclu-
sively elucidated. The timing of embolization of PCVMCCs to the
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FIGURE 7 | A 4-month-old girl presented with a rapidly growing infantile
hemangioma on the right cheek, lower lid, and orbit with ocular dystopia
(A) shown on a T2-weighted MRI scan (B). Accelerated involution of the
lesion with equalization of the globe 7 days (C), 4 weeks (D), and 5 months
(E) following institution of propranolol therapy at 2 mg/kg/day. Reproduced
with permission from Plastic and Reconstructive Surgery (70).
FIGURE 8 | A 22-week-old girl with a 7 cm×10 cm proliferating infantile
hemangioma in the right cervico-facial area causing significant tissue
distortion before (A,B), 3 weeks (C), and 6 months (D,E) after
administration of captopril at 1.5 mg/kg/day resulting in accelerated
involution. Reproduced with permission from British Journal of
Dermatology (66).
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fetus in relation to the timing of neural crest cell migration down
their somitic migration routes, may account for the morphology
(discrete or segmental) of the lesions (32, 91).
There is strong evidence of the involvement of the VEGFR-
2 and its ligand VEGF-A (46, 48, 51) and the IGF-2 ligand in
promoting cellular proliferation (42, 55), and the TRAIL-OPG
anti-apoptotic pathway in preventing cellular apoptosis (58) in IH
(Figure 6).
The discovery of the role of the RAS in the biology of IH
(25) provides a plausible explanation for the programed biologic
behavior and the β-blocker-induced accelerated involution of this
tumor (25) (Figure 6). The observation that the vasoactive pep-
tide, ATII, promotes cellular proliferation in IH predominantly via
its action on the ATIIR2 isoform (63) is significant. The role of the
RAS in the biology of IH is further supported by the effect of cap-
topril, an ACE inhibitor, in inducing accelerated involution of IH
(66) (Figure 6).
The discovery of the critical role of RAS in IH represents a novel
and fascinating paradigm shift in the understanding of human
development, IH, and other tumors in general (92).
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